Abstract
Clinical genetic studies propose a strong genetic contribution to the pathogenesis of anxiety disorders with a heritability of about 30-67%. The present review will give an overview of linkage studies, association studies and genome-wide association studies (GWAS) yielding support for some candidate genes. Additionally, first evidence for gene-environment interactions between candidate genes of anxiety disorders and stressful life events will be reported. On a systems level, neural activation correlates of anxiety-relevant emotional processing and neurophysiological measures such as peripheral sympathetic activity or the startle reflex have been shown to be potentially driven by vulnerability genes of anxiety disorders. Promising current approaches to further dissect the genetic underpinnings of anxiety disorders such as next generation sequencing, epigenetic analyses and pharmaco-/ psychotherapy-genetics will be presented. Genetic research in anxiety disorders will be discussed with respect to its potential benefit for future efforts to develop innovative and individually tailored therapeutic approaches for patients with anxiety disorders.
Keywords: Linkage, association, genome-wide association, gene-environment interaction, imaging genetics, epigenetics, pharmacogenetics
Current Pharmaceutical Design
Title:Genetics of Anxiety Disorders - Status Quo and Quo Vadis
Volume: 18 Issue: 35
Author(s): Katharina Domschke and Jurgen Deckert
Affiliation:
Keywords: Linkage, association, genome-wide association, gene-environment interaction, imaging genetics, epigenetics, pharmacogenetics
Abstract: Clinical genetic studies propose a strong genetic contribution to the pathogenesis of anxiety disorders with a heritability of about 30-67%. The present review will give an overview of linkage studies, association studies and genome-wide association studies (GWAS) yielding support for some candidate genes. Additionally, first evidence for gene-environment interactions between candidate genes of anxiety disorders and stressful life events will be reported. On a systems level, neural activation correlates of anxiety-relevant emotional processing and neurophysiological measures such as peripheral sympathetic activity or the startle reflex have been shown to be potentially driven by vulnerability genes of anxiety disorders. Promising current approaches to further dissect the genetic underpinnings of anxiety disorders such as next generation sequencing, epigenetic analyses and pharmaco-/ psychotherapy-genetics will be presented. Genetic research in anxiety disorders will be discussed with respect to its potential benefit for future efforts to develop innovative and individually tailored therapeutic approaches for patients with anxiety disorders.
Export Options
About this article
Cite this article as:
Domschke Katharina and Deckert Jurgen, Genetics of Anxiety Disorders - Status Quo and Quo Vadis, Current Pharmaceutical Design 2012; 18 (35) . https://dx.doi.org/10.2174/138161212803530781
DOI https://dx.doi.org/10.2174/138161212803530781 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
subject Index To Volume 1
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents From QTL to Candidate Gene: A Genetic Approach to Alcoholism Research
Current Drug Abuse Reviews Nociceptin/Orphanin FQ Peptide Receptors: Pharmacology and Clinical Implications
Current Drug Targets Non-Analgesic Effects of Opioids: The Interaction of Opioids with Bone and Joints
Current Pharmaceutical Design Halving Your Cake and Eating it, Too: A Case-based Discussion and Review of Metabolic Rehabilitation for Obese Adults with Diabetes
Current Diabetes Reviews Neuroleptics and Migraine
Central Nervous System Agents in Medicinal Chemistry Castration Resistant Prostate Cancer: From Emerging Molecular Pathways to Targeted Therapeutic Approaches
Clinical Cancer Drugs Phenotypes and Enviromental Factors: Their Influence in PCOS
Current Pharmaceutical Design Neuroprotection by vitamin C against ethanol -induced neuroinflammation associated neurodegeneration in developing rat brain
CNS & Neurological Disorders - Drug Targets Gastrointestinal Motility and Functional Gastrointestinal Diseases
Current Pharmaceutical Design Sirtuin Modulators: Mechanisms and Potential Clinical Implications
Current Medicinal Chemistry Sex Differences in Alcohol Use Disorder
Current Medicinal Chemistry Neuropeptide Y and Cancer Anorexia
Current Medicinal Chemistry - Central Nervous System Agents Neuroprotection and Sex Steroid Hormones: Evidence of Estradiol- Mediated Protection in Hypertensive Encephalopathy
Mini-Reviews in Medicinal Chemistry The Emerging Roles of Leptin and Ghrelin in Cardiovascular Physiology and Pathophysiology
Current Vascular Pharmacology Cholinergic Treatment of Traumatic Brain Injury
Current Drug Therapy Volumetric Analysis of the Hypothalamus, Amygdala and Hippocampus in Non-Suicidal and Suicidal Mood Disorder Patients – A Post-Mortem Study
CNS & Neurological Disorders - Drug Targets Lifelong Endocrine Fluctuations and Related Cognitive Disorders
Current Pharmaceutical Design Cytochrome P450 in the Brain ; A Review
Current Drug Metabolism Suppression of TLR Signaling by Targeting TIR domain-Containing Proteins
Current Protein & Peptide Science